- For QC teams: the recall puts potency testing at the center of the quality event.
- For QA teams: it raises questions around affected-lot control and recall documentation.
- supply and safety teams: must prevent further distribution while ensuring patients receive appropriate guidance through healthcare providers.
Superpotent Thyroid Tablets Trigger Recall as Patient Safety Risk Emerges
Vitruvias said testing confirmed the potential for lot 504950 to be superpotent. Thyroid, USP is a natural preparation derived from porcine thyroid glands and contains levothyroxine and liothyronine for treating hypothyroidism.
Excess thyroid hormone can cause hyperthyroidism. Possible effects include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate and heart rhythm disturbances.
Moreover, the company announcement identifies elderly patients, pregnant women and infants as groups at greater risk, particularly after extended exposure. However, Vitruvias said it has received no reports of adverse events known to be associated with the recalled lot.
1,955 Units Sold: How Far Did the Recalled Thyroid Lot Reach?
The recall applies to Thyroid Tablets, USP 30 mg, NDC 69680-166-00, lot 504950, with an expiration date of September 30, 2026.
| Product | Lot | Expiry | Units Released | Units Sold | Distribution Period |
|---|---|---|---|---|---|
|
Thyroid Tablets, USP 30 mg |
504950 |
Sept. 30, 2026 |
3,655 |
1,955 |
Jan. 31–Sept. 30, 2025 |
Vitruvias distributed the affected lot nationwide to its direct accounts. The company is now notifying wholesalers to discontinue distribution and is arranging destruction of recalled product. Patients using the affected lot should not stop treatment without contacting their healthcare provider for guidance or a replacement prescription.
FDA notes that it posts company recall announcements as a public service and does not endorse the company or product. The recall is being conducted with the agency’s knowledge.
What QA Teams Should Check After the Vitruvias Thyroid Recall
For pharmaceutical quality teams, the immediate response should remain focused on the affected lot. Teams should confirm whether lot 504950 remains in inventory or distribution channels, stop further distribution where applicable, preserve relevant testing and batch documentation, support recall communications, and monitor complaints or safety reports connected with the product.
If post-distribution testing identifies a potential potency problem, which evidence should QA review first to determine the scope of the quality event?
What Happens Next as Vitruvias Removes the Recalled Thyroid Lot?
Vitruvias is continuing wholesaler notification and arranging destruction of affected product. Therefore, quality and regulatory teams should watch for any FDA updates, any change in the number of affected lots, and any adverse-event reports that may later be associated with the recalled product.
How Strong QMS Controls Help Manage Pharmaceutical Recall Risk
Zamann Pharma’s Quality Management System support covers batch-record review, non-conformity management, CAPA, risk management and market complaints. Pharmaceutical teams reviewing how they handle product-quality events can explore this service for practical quality-system support.
Source: FDA